Novo Nordisk A/S | NOVOB - Selling And Administration Expenses


Novo Nordisk reported DKK16.31B in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Bausch Health Companies USD 834M 67M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Merck USD 2.86B 25M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Novo Nordisk DKK 16.31B 3.09B Jun/2026
Novo Nordisk DKK 2.54B 10.68B Jun/2026
Pacira USD 950.8M 858.99M Sep/2026
Sanofi EUR 2.31B 325M Sep/2026
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026